close Video

NEW You can now listen to Fox News articles!

A new treatment strategy tested by UCLA researchers could offer new hope for men whose prostate cancer has returned after initial treatment.

This approach could also help delay the need for hormone therapy, which can have burdensome side effects.

The findings, which were presented at the annual American Society for Radiation Oncology (ASTRO) meeting this week, showed that combining a targeted radioactive drug with standard radiation therapy more than doubled the amount of time patients remained free of disease progression.

NEW BREAST CANCER DRUG WINS FDA APPROVAL AFTER SLASHING PROGRESSION RISK BY NEARLY 40%

The study focused on men with a form of cancer recurrence where the disease had returned in only a few isolate

See Full Page